Home › Trials › NCT07563205

Amivantamab with platinum chemotherapy for metastatic EGFR‑mutant non‑small cell lung cancer

Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer as Part of an Early Access Program

Observational Groupe Francais De Pneumo-Cancerologie · NCT07563205

This study will try giving amivantamab together with platinum chemotherapy to adults with metastatic NSCLC who have specific EGFR mutations to see how long their cancer stays controlled and how safe the treatment is.

Quick facts

Study typeObservational
Enrollment100 (estimated)
Ages18 Years and up
SexAll
SponsorGroupe Francais De Pneumo-Cancerologie Academic / other
Drugs / interventionsamivantamab, osimertinib, chemotherapy
Locations16 sites (Aix-en-Provence and 15 other locations)
Trial IDNCT07563205 on ClinicalTrials.gov

What this trial studies

This multicenter observational study collects real-world outcomes from adults with metastatic NSCLC who receive amivantamab plus platinum-based chemotherapy through an early access program. It enrolls two cohorts: Cohort A includes patients with EGFR exon 20 insertions treated with the combination as first-line therapy, and Cohort B includes patients with EGFR exon 19 or 21 mutations treated with the combination after prior osimertinib. Investigators will record time to disease progression (progression-free survival), other clinical outcomes, and safety events using routine clinical data. The study is non-randomized and aims to describe effectiveness and tolerability across participating French hospitals.

Who should consider this trial

Good fit: Adults with metastatic NSCLC who have an EGFR exon 20 insertion receiving amivantamab plus platinum chemotherapy in first line, or adults with EGFR exon 19 or 21 mutations receiving the combination after osimertinib, and who are covered by French National Health Insurance or an approved payer.

Not a fit: Patients without the specified EGFR mutations, those with earlier-stage disease, or people not receiving amivantamab through the early access program are unlikely to be eligible or to benefit from this study.

Why it matters

Potential benefit: If successful, the study could show that adding amivantamab to chemotherapy helps people with EGFR-mutant metastatic NSCLC stay progression-free longer and clarify the combination's real-world safety.

How similar studies have performed: Prior clinical trials have shown activity of amivantamab in EGFR exon 20–mutant NSCLC, but combining amivantamab with platinum chemotherapy in these exact real-world settings is less well documented and is the focus of this observational effort.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patient over 18 years old
* Cohort A: Patient with metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion treated with amivantamab-platimum based chemotherapy via an early access program in first line setting.
* Cohort B: Patient with metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 19 or 21 treated with amivantamab-platimum based chemotherapy post osimertinib (with or without chemotherapy) via an early access program.
* Patient covered by the French National Health Insurance system or by an approved third-party payer
* Patient who does not object to the collection of their personal data for research purposes (an information sheet will be provided to all living participants; for deceased participants, documented non-opposition in the medical record is not required)

Exclusion Criteria:

* Patient placed under legal guardianship or subject to a protective legal measure
* Patient who explicitly refuses the collection or use of their personal data for research purposes
* Patient not enrolled, managed, or followed at the investigating site by a qualified site investigator

Where this trial is running

Aix-en-Provence and 15 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Non-Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNon Small Cell Lung Cancer NSCLCNon Small Cell Lung CarcinomaNSCLCEGFREGFR Exon 20 Insertion MutationEGFR Exon 19 Deletion Mutation
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.